APOLLOHOSP.NS · NSI · Healthcare
Apollo Hospitals Enterprise Limited
Also onConsensus Drift
Implied value per share
INR 1606.47
Market price
INR 8944.50
Implied upside
-82.0%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Current EV/EBITDA of 35.8x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (INR). Outflows negative.
| Line | FY27 | FY28 | FY29 | FY30 | FY31 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | INR 286.1bn | INR 328.6bn | INR 377.3bn | INR 433.4bn | INR 497.7bn | +14.8% |
| EBIT | INR 28.7bn | INR 32.9bn | INR 37.8bn | INR 43.4bn | INR 49.9bn | +14.8% |
| NOPAT | INR 21.4bn | INR 24.6bn | INR 28.3bn | INR 32.5bn | INR 37.3bn | +14.8% |
| Add depreciation & amortisation | INR 10.3bn | INR 11.8bn | INR 13.6bn | INR 15.6bn | INR 17.9bn | +14.8% |
| Less capital expenditure | INR -20.5bn | INR -23.6bn | INR -27.1bn | INR -31.1bn | INR -35.7bn | +14.8% |
| Less increase in working capital | INR -6.3bn | INR -7.2bn | INR -8.3bn | INR -9.5bn | INR -10.9bn | +14.8% |
| Free cashflow to firm | INR 4.9bn | INR 5.7bn | INR 6.5bn | INR 7.5bn | INR 8.6bn | +14.8% |
| Discount factor | 0.9528 | 0.8649 | 0.7851 | 0.7127 | 0.6470 | - |
| Present value | INR 4.7bn | INR 4.9bn | INR 5.1bn | INR 5.3bn | INR 5.6bn | +4.3% |
| Present Value Of The Forecast | INR 25.7bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 6.80% | INR assumption - no free live source available for this market (assumption) |
| Equity risk premium | 8.00% | Market assumption |
| Beta | 0.462 | Reported 0.197, pulled toward 1.0 (Blume) |
| Cost of equity | 10.50% | Risk-free + beta x equity risk premium |
| Cost of debt | 6.80% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | INR 1286.1bn | 93.8% of capital |
| Total debt | INR 84.9bn | 6.2% of capital, book value as a proxy |
| Tax rate | 25.2% | Effective, capped at statutory |
| WACC | 10.16% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
91% of EV
- Forecast FCFF, final year
- INR 8.6bn
- Capex at depreciation, working capital in reinvestment
- INR 38.5bn
- Less reinvestment at g/ROIC (18.5% of NOPAT)
- INR -7.1bn
- Capitalised
- INR 31.4bn
- ROIC (reported)
- 13.5%
- Terminal value, undiscounted
- INR 420.2bn
- Terminal value, discounted
- INR 271.9bn
- Enterprise value
- INR 297.5bn
- Less net debt
- INR 66.4bn
- Equity value
- INR 231.1bn
Exit at 20.0x EBITDA
97% of EV
- Terminal value, undiscounted
- INR 1356.5bn
- Terminal value, discounted
- INR 877.6bn
- Enterprise value
- INR 903.3bn
- Less net debt
- INR 66.4bn
- Equity value
- INR 836.9bn
Spread between methods: 113%.
Sensitivity
Value per share (INR) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 8.16% | 2275.10 | 2380.14 | 2502.50 | 2647.21 | 2821.48 |
| 9.16% | 1847.96 | 1912.37 | 1985.44 | 2069.29 | 2166.77 |
| 10.16% | 1522.52 | 1562.32 | 1606.48 | 1655.91 | 1711.80 |
| 11.16% | 1267.03 | 1291.28 | 1317.62 | 1346.43 | 1378.20 |
| 12.16% | 1061.69 | 1075.80 | 1090.75 | 1106.70 | 1123.80 |
Outlined: this model. Green text: above today's price of 8944.50. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 14.8% | 61.0% | +46.1pp |
| EBIT margin | 10.0% | 38.3% | +28.3pp |
| Discount rate | 10.2% | 4.5% | -5.7pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.